Dr. Maike Buchner-Mayr

Max Eder Research Group

Negative feedback inhibition as a novel therapeutic approach in chronic lymphocytic leukemia

Institute for Clinical Chemistry and Pathobiochemistry

Academic Career and Research Areas

Maike Buchner received her Master in Molecular Medicine in Freiburg in 2006. She completed her PhD with honors in 2010 with the project ‚Inhibition of Microenvironmental Pathways: a Novel Therapeutic Approach in Chronic Lymphocytic Leukemia’ in the laboratory of Hendrik Veelken in Freiburg. She conducted her postdoctoral studies at the University of California, San Francisco in the laboratory if Markus Müschen. Here, she studied normal B cell development and transformation to acute lymphoblastic leukemia (ALL). She contributed to studies involving signaling thresholds in ALL and negative feedback inhibition. With these insights together with her PhD experience, her current research is focusing on negative feedback inhibition in CLL.

 

The focus of Maike Buchner’s research is the dissection of divergent signaling events in malignant versus normal B cells. In particular downstream of the B cell receptor and the regulation of signaling strength. Her focus is on chronic lymphocytic leukemia. Via analysis of primary patient samples and healthy donors as well as preclinical models, she investigates the impact of inhibition of negative regulators on different cell types.

Awards

  • Max Eder-Stipendium, Deutsche Krebshilfe (2016)
  • Abstract Achievement Award, American Society of Hematology (2015)
  • Rückkehrer Stipendium, DAAD (2014)
  • Abstract Achievement Award, American Society of Hematology (2013)
  • Abstract Achievement Award, American Society of Hematology (2012)
  • Promotionspreis, Medizinsche Fakultät Freiburg (2010)
  • Promotion ‚summa cum laude’, Fakultät für Biologie / Fakultät für Medizin (2010)
  • Promotionsstipendium, Medizinsche Fakultät Freiburg (2006)

Ecker, V.*, Stumpf, M.*, Brandmeier, L., Neumayer, T., Ringshausen, I., Pfeuffer, L., Engleitner, T., Ringshausen, I., Nelson, L., Jücker, M., Wanninger, S., Zenz, T., Wendtner, C., Manske, K., Steiger, K., Rad, R., Müschen, M., Ruland, J., Buchner M. (2021) Targeted PI3K/AKT-hyperactivation induces necroptotic cell death in chronic lymphocytic leukemia. Nat Commun. 2021 Jun 10;12(1):3526.

Abstract

Alankus, B.*, Ecker, V.*, Vahl, N., Braun, M., Weichert, W., Macher-Göppinger, S., Gehring, T., Neumayer, T., Zenz, T., Buchner, M.#, Ruland, J.# (2021). Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. J Exp Med. Feb 1;218(2):e20200517.#Co-Senior authors.

Abstract

Patzelt, T., Keppler, SJ., Gorka, O., Thöne, S., Wartewig, T., Förster, I., Lang, R., Buchner, M.§, Ruland, J.§ (2018). Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells. Proc Natl Acad Sci U S A. Mar 20;115(12):3120-3125.§Corresponding authors.

Abstract

Chen Z*, Seyedmehdi S*, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber T, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh M, Jung JU, Coligan JE, Bolland S, Mak T, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.: „Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia“ Nature. 2015 May 21;521(7552):357-61.

Abstract

Buchner M, Park E, Geng H, Klemm L, Schjerven H, Paietta E, Kopanja D, Raychaudhuri P, Müschen M.: „Identification of FOXM1 as therapeutic target in B cell lineage acute lymphoblastic leukemia“ Nat Commun. 2015 Mar 10;6:6471.

Abstract